Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | WNT1 | P04628 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK3 | P49761 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641186 | 0.86 | GSK3B (0.66) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL3537308 | 0.81 | GSK3B (0.62) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL3540845 | 0.80 | GSK3B (0.61) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL3538874 | 0.79 | GSK3B (0.54) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL3535776 | 0.79 | GSK3B (1.00) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL3531848 | 0.78 | KDR (0.61) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL3539324 | 0.78 | GSK3B (0.58) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL3540878 | 0.76 | GSK3B (0.75) | GSK3BKDRPDGFRBFGFR1NPC1 | |
| SCHEMBL15416579 | 0.76 | KDM4E (0.70) | NPC1KDM4ELDHAEPHX2ALDH1A1 | |
| SCHEMBL3542928 | 0.76 | GSK3B (0.57) | GSK3BKDRPDGFRBFGFR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | claimed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| EP-1725543-B1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1725543-B1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| EP-1725543-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | GSK3B, GSK3A, PYGB | GSK3B 1/4885KDR 2532/4885PDGFRB 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.